J&J CEO Credits Trump Tax Policies for $55 Billion US Investment Push
Johnson & Johnson Chairman and CEO Joaquin Duato credited Trump administration tax policies for enabling the healthcare giant’s $55 billion U.S. investment commitment, telling Fox Business that a competitive tax environment has allowed the company to bring manufacturing back to American soil. The remarks came one day after J&J announced a $1 billion+ investment in a Vision manufacturing facility in Jacksonville, Florida.
A $55 Billion Bet on America
The $55 billion commitment, first announced in March 2025, represents a 25% increase in U.S. investment compared to the previous four-year period. According to a Johnson & Johnson press release, the investment spans manufacturing, research and development, and technology infrastructure through early 2029.
“We have the best talent, we have the best investment environment and, very importantly, we have now the tax policy enacted with this administration that has enabled us to be competitive,” Duato said on Fox Business’ “Mornings with Maria.” “We’re playing with a hand tied to our back compared to companies that were domiciled outside of the U.S. Now we can create high-skilled jobs, we can invest in America, and we can be competitive.”
Jacksonville Gets $1 Billion+ Vision Manufacturing Hub
On June 15, 2026, J&J announced a more than $1 billion investment in Jacksonville, Florida, for a new state-of-the-art distribution facility and advanced manufacturing and packaging technologies for its ACUVUE® contact lens brand. The company stated that construction is underway with the goal of being fully operational in 2028.
Johnson & Johnson has operated in Jacksonville since 1981, now employing approximately 3,500 people across more than 1.5 million square feet of facilities. The company manufactures over 1.7 billion ACUVUE lenses annually and contributes an estimated $6 billion per year to Florida’s economy.
Jacksonville Mayor Donna Deegan welcomed the investment, calling it “a strong vote of confidence in Jacksonville, our workforce, and our future.” U.S. Senator Rick Scott praised the move for strengthening “America’s healthcare supply chain to better serve patients,” while Senator Ashley Moody highlighted that “companies are moving to Florida in droves.”
The North Carolina Biologics Facility
The broader investment plan includes a $2 billion+ biologics manufacturing facility in Wilson, North Carolina, where groundbreaking occurred in March 2025. The 500,000-square-foot facility is expected to support approximately 5,000 construction jobs and create over 500 permanent positions, with a projected $3 billion economic impact across the state in its first decade of operations.
Three additional advanced manufacturing facilities are planned across J&J’s Innovative Medicine and MedTech businesses, with locations to be announced.
Tax Policy and the Pharma Reshoring Wave
Duato’s explicit reference to “the tax policy enacted with this administration” points to the 2017 Tax Cuts & Jobs Act (TCJA), which reduced the corporate tax rate from 35% to 21% and shifted to a territorial tax system. The CEO argued these changes have made U.S. manufacturing competitive again after years of companies facing disadvantages compared to foreign-based competitors.
J&J’s announcement is part of a broader pharmaceutical reshoring trend. As BioPharma Dive reported, Eli Lilly, Merck & Co., and Amgen have all announced major U.S. manufacturing expansions, driven by the 2017 tax cuts, tariff risks from overseas production, and growing domestic demand. The Trump administration’s “America First” investment policies have further encouraged companies to expand domestic capacity.
The TrumpRx Agreement
In January 2026, J&J reached a voluntary agreement with the Trump administration to participate in TrumpRx, a direct-to-patient discount platform. According to Pharmaceutical Executive, the agreement includes aligning U.S. drug pricing with other developed countries and provides J&J’s pharmaceutical products with exemptions from certain tariffs.
Pipeline Confidence and Growth Outlook
Duato expressed strong confidence in the company’s future, highlighting Icotyde, a newly-approved once-daily oral treatment for psoriasis and psoriatic arthritis designed to rival injectable biologics. He also noted that J&J is seeking approval for its first robotic surgical system.
“We are not a one-trick pony company. We’re a company with a stable of blockbusters,” Duato said. “We have 28 platforms at Johnson & Johnson of more than $1 billion, so that gives us the confidence to be so bold to say we have line of sight to double-digit growth for Johnson & Johnson by the end of the decade.”
What to Watch
The $55 billion investment plan positions J&J at the intersection of corporate tax policy, pharmaceutical reshoring, and the broader “America First” economic agenda. Key questions remain: where will the three additional manufacturing facilities be located, how will the Jacksonville facility’s 2028 operational target align with the 2029 expiration of certain TCJA provisions, and what impact will tariff exemptions have on J&J’s global supply chain? The company’s total U.S. economic impact is already estimated at more than $100 billion per year — a figure that is set to grow substantially as these investments come online.